Mehanna H, et al. - In this open-label randomized controlled phase 3 trial at 32 head and neck treatment centers in Ireland, the Netherlands, and the UK, researchers assessed 334 candidates to estimate the efficiency of radiotherapy plus cisplatin vs cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV) from Nov 12, 2012, to Oct 1, 2016. They observed no significant differences in overall all-grade toxicity of the two therapies. But, they found a notable difference between cisplatin and cetuximab in 2-year overall survival and 2-year recurrence. They suggested cisplatin plus radiotherapy as a standard of care for HPV-positive low-risk cases who could endure cisplatin.